IP Library › Granted Patent US 7,604,990
Granted Patent B2
US 7,604,990 · App. 11/006,300 · Granted Oct 20, 2009

Methods of regulating differentiation in stem cells

Assignee: ES Cell International Pte Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,604,990
App. No.
11/006,300
Granted
Oct 20, 2009
Kind
B2
Abstract

The present invention provides methods, media and compositions capable of modulating the differentiation of stem cells. Applicants have discovered that agonists of lysophospholipid receptors and ligands of class III tyrosine kinase receptors are useful in preventing the spontaneous differentiation of stem cells. The ligands and agonists may be used alone, or in combination where they have a synergistic effect. Also provided are cells produced using the methods and media, and methods of treating stem cell related diseases using the compositions described herein. Methods of identifying compounds useful in finding other agents useful in the modulation of stem cell differentiation are also disclosed.

Claims (25)

1. A serum free or substantially serum free medium useful for modulating spontaneous differentiation of a stem cell, comprising an agonist of the LPL receptor and a ligand of a class III tyrosine kinase receptor, wherein the agonist is selected from the group consisting of S1P, dihydro-S1P, LPA, PAF and SPC.

2. A medium according to claim 1 wherein the modulation is inhibition of differentiation.

3. A medium according to claim 1 wherein the medium is serum free.

4. A medium according to claim 1 wherein the LPL receptor is selected from the group consisting of S1P1, S1P2, and S1P3.

5. A medium according to claim 1 wherein the agonist is S1P.

6. A medium according to claim 1 wherein the agonist is dihydro S1P.

7. A medium according to claim 1 comprising TNF alpha, NGF (nerve growth factor), a muscarinic acetylcholine agonist, a serum or phorbol ester.

8. A medium according to claim 1 wherein the stem cell is derived from foetal tissue or adult tissue.

9. A medium according to claim 8 wherein the stem cell is an ES cell.

10. A medium according to claim 8 wherein the stem cell is a hES cell.

11. A medium according to claim 1 wherein the base medium is a standard serum free medium.

12. A medium according to claim 1 comprising 25 mM Hepes.

13. A medium according to claim 11 wherein the base medium is based on DMEM supplemented with insulin, transferrin and selenium.

14. A medium according to claim 1 wherein the agonist is S1P and is present in the medium at a concentration of from 0.1 μM to 10 μM.

15. A medium according to claim 1 wherein the agonist is present in the medium at a concentration of about 10 μM.

16. A medium according to claim 1 wherein the tyrosine kinase receptor is PDGFR-α or PDGFR-β.

17. A medium according to claim 1 wherein the ligand is a PDGF or a functional equivalent thereof.

18. A medium according to claim 17 wherein the PDGF is PDGFaa, PDGFab or PDGFbb.

19. A serum-free or substantially serum-free medium useful for modulating spontaneous differentiation of a stem cell, comprising an agonist of a LPL receptor wherein said agonist is PAF.

20. A medium according to claim 19 wherein the modulation is inhibition of differentiation.

21. A medium according to claim 19 wherein the medium is serum free.

22. A medium according to claim 19 wherein the base medium is a standard serum free medium.

23. A medium according to claim 19 comprising 25 mM Hepes.

24. A medium according to claim 22 wherein the base medium is based on DMEM supplemented with insulin, transferring and selenium.

25. A medium according to claim 19 wherein the agonist is present in the medium at a concentration of about 10 μM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2005
From: PEBAY, ALICE MARIE; PERA, MARTIN FREDERICK
To: ES CELL INTERNATIONAL PTE LTD.
Reel/Frame 016876/0804 →
Priority Claims (4)
AU PS2860 · Jun 7, 2002 · national
AU PS2861 · Jun 7, 2002 · national
AU 2003901313 · Mar 21, 2003 · national
AU 2003902729 · Jun 2, 2003 · national
Continuity (2)
Continuation PCTAU030071300 · Jun 6, 2003
Related Publication 20050266553A1 · Dec 1, 2005